LBA70 OSIRAM-1: A Multicenter, Open Label, Randomized Phase II Study of Osimertinib Plus Ramucirumab Versus Osimertinib Alone As Initial Chemotherapy for EGFR Mutation-Positive Non-Squamous Non-Small Cell Lung Cancer (TORG1833)
Annals of Oncology（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要